Tezepelumab-ekko side effects

What is tezepelumab-ekko?

Tezepelumab-ekko side effectsTezepelumab-ekko side effects are unwanted reactions that may be experienced while using this drug

Tezepelumab-ekko is a human monoclonal antibody immunoglobulin G2 (IgG2) generated in Chinese hamster ovary (CHO) cells using recombinant DNA technology. It is a thymic stromal lymphopoietin (TSLP) blocker. The molecular weight of tezepelumab-ekko is approximately 147 kDa.

Tezepelumab-ekko injection is a single-dose vial or single-dose pre-filled syringe of sterile, preservative-free, clear to opalescent, colorless to light yellow solution for subcutaneous injection.

Each single-dose vial or pre-filled syringe contains 1.91 mL of tezepelumab-ekko, 2.8 mg of glacial acetic acid, 48 mg of L-proline, 0.19 mg of polysorbate 80, sodium hydroxide, and water for injection. The pH of the water is 5.2.

Tezepelumab-ekko is a prescribed medicine that is used in conjunction with other asthma medications to treat severe asthma in patients who are 12 years old or older whose asthma isn’t controlled by their current asthma medication.

Tezepelumab-ekko is a great way to stop serious asthma attacks (exacerbations) and improve your breathing.

Tezepelumab-ekko is not intended to treat breathing issues that arise suddenly. Inform your doctor when your asthma doesn’t improve or becomes worse following the start of treatments with Tezepelumab-ekko .

It isn’t known whether this medication can be used safely and effectively for children younger than 12 years old. age.

Who should not receive Tezepelumab-ekko ?

Do not get this medication if:

Prior to receiving Tezepelumab-ekko

Before you get this medication,  inform your healthcare provider of the medical conditions you suffer from for example if you

Mechanism of Action

Tezepelumab-ekko is a thymic stromal lymphopoietin (TSLP) blocker, a human monoclonal antibody IgG2 that binds to human TSLP and blocks its interaction with the heterodimeric TSLP receptor with a dissociation constant of 15.8 pM. TSLP is a cytokine produced mostly by epithelial cells that has a role in the asthma inflammatory cascade.

Inflammation of the airways is a key factor in the development of asthma. Airway inflammation is caused by a variety of cell types (mast cells, eosinophils, neutrophils, macrophages, lymphocytes, and ILC2 cells), as well as mediators (histamine, eicosanoids, leukotrienes, and cytokines). Blocking TSLP with tezepelumab-ekko lowers inflammatory biomarkers and cytokines like blood eosinophils, airway submucosal eosinophils, IgE, FeNO, IL-5, and IL-13; however, the mechanism of tezepelumab-ekko action in asthma has yet to be determined.

What other drugs can impact Tezepelumab-ekko ?

Discuss with your doctor the medications you are taking such as prescription and over-the-counter supplements including vitamins, supplements, and herbal supplements. Do not alter or stop taking corticosteroid medications or other asthma medicine unless your doctor advises you to.

How do I get Tezepelumab-ekko ?

Tezepelumab-ekko side effects

For consumers

This medication may cause serious side effects, including:

The most frequent adverse effects are:

This is not the only list of the possible adverse consequences. Consult your physician to seek medical advice on adverse effects. You can report symptoms to FDA at 1-800-FDA-1088.

For professionals

General

Respiratory

Immunologic

Musculoskeletal

Local

How Supplied

The injections are a preservative-free, sterile clear to opalescent clear to light yellow, colorless solution that is available as a single-dose vial or single-dose vial with a 27 gauge fixed 1/2 inch needle, with needle covers. The cap for the needle and vial stopper is not made from natural latex rubber.

 This is available in the following formats:

Storage and Handling

Store in a cool, dry place between 36degF and 46degF (2degC to 8 degC). If needed, Tezepelumab-ekko may be kept at room temperature, ranging from 68degF and [email protected] (20degC between 25 and 25degC) for up to 30 days. Don’t put it back in the refrigerator until Tezepelumab-ekko is at temperatures of room temperature. Once removed from the refrigerator Tezepelumab-ekko is to be utilized within 30 days or removed from the refrigerator.

Keep Tezepelumab-ekko in the original packaging to keep it safe from sunlight until the time of use.

Avoid freezing. Don’t shake. Avoid exposure to heat.

Label

Tezepelumab-ekko side effects

More details

Always consult your doctor to make sure the information presented on this page is applicable to your particular situation.

Leave a Reply